“The Next Generation of Schizophrenia Treatment is Here” (Psychiatrist dot com) - 26 March 2025
Quote:
Clinical relevance: Research highlights D-serine as a key modulator of NMDA receptors, with low D-serine levels linked to schizophrenia.
- Luvadaxistat showed cognitive biomarker improvements in schizophrenia patients at a 50 mg dose, suggesting a non-linear dose response.
- Ω-NaBe shows improved absorption and efficacy, effectively addressing all three major schizophrenia symptom domains.
- Further studies are required to validate results, understand the inverted-U dose response, and assess long-term impacts.